American Society of Hematology

Figure 4.

$METTL3 depletion attenuates the effect of PRMT5 inhibition on BPDCN cells. (A) Reduction in mRNA expression of METTL3 and METTL14 after 72 hours of shRNA KD (normalized to NT). (B) CAL-1 cell growth after 72 hours shRNA KD, normalized to NT. (C) Expression of METTL3 upon KO induction with 2 independent METTL3 sgRNAs (72 hours, 3 µg/mL Dox). (D) mRNA expression of METTL3, 72 hours after Dox induction, normalized to NT. (E) CAL-1 cell growth after METTL3 KO (72 hours, 3 µg/mL Dox), normalized to noninduced. (F) mRNA expression of PRMT5 and METTL3 in GSK595-treated KO cells. (G) Cell growth of CAS9 and METTL3 KO cells after GSK595 treatment, normalized to DMSO. (H) Lack of cleaved caspase-3 activation upon treatment in KO cells only. (I) mRNA expression of PUMA in GSK595-treated KO cells. (J) Quantification of the apoptotic fraction. Data are shown as mean ± standard error of the mean of 3 independent experiments. *P < .05; **P < .01; ***P < .001.$

METTL3 depletion attenuates the effect of PRMT5 inhibition on BPDCN cells. (A) Reduction in mRNA expression of METTL3 and METTL14 after 72 hours of shRNA KD (normalized to NT). (B) CAL-1 cell growth after 72 hours shRNA KD, normalized to NT. (C) Expression of METTL3 upon KO induction with 2 independent METTL3 sgRNAs (72 hours, 3 µg/mL Dox). (D) mRNA expression of METTL3, 72 hours after Dox induction, normalized to NT. (E) CAL-1 cell growth after METTL3 KO (72 hours, 3 µg/mL Dox), normalized to noninduced. (F) mRNA expression of PRMT5 and METTL3 in GSK595-treated KO cells. (G) Cell growth of CAS9 and METTL3 KO cells after GSK595 treatment, normalized to DMSO. (H) Lack of cleaved caspase-3 activation upon treatment in KO cells only. (I) mRNA expression of PUMA in GSK595-treated KO cells. (J) Quantification of the apoptotic fraction. Data are shown as mean ± standard error of the mean of 3 independent experiments. *P < .05; **P < .01; ***P < .001.

This Feature Is Available To Subscribers Only